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Abstract: It is well appreciated that ethnicity influences the natural history and immune responses
during a chronic hepatitis B infection. In this study, we explore the effect of ethnicity and treatment
cessation on Hepatitis B surface Antigen (HBsAg) seroclearance in patients with Nucleos(t)ide
Analogue (NA)-induced Hepatitis B e Antigen (HBeAg) seroconversion. We performed a multi-ethnic,
multicentric observational cohort study. The analyzed cohort consisted of 178 mono-infected,
predominantly male (75.3%) chronic hepatitis B patients of mixed ethnicity (44.4% Asians, 48.9%
Caucasians) with nucleos(t)ide analogue-induced HBeAg seroconversion. Treatment was withdrawn
in 105 patients and continued in 73, leading to HBsAg loss in 14 patients off- and 16 patients
on-treatment, respectively. Overall, HBsAg loss rates were not affected by treatment cessation
(hazard ratio 1.45, p = 0.372), regardless of consolidation treatment duration. Caucasian ethnicity
was associated with an increased chance of HBsAg loss (hazard ratio 6.70, p = 0.001), but hepatitis
B virus genotype was not (p = 0.812). In conclusion, ethnicity is the most important determinant
for HBsAg loss after NA-induced HBeAg seroconversion, with up to six-fold higher HBsAg loss
rates in Caucasians compared to Asians, irrespective of treatment cessation and consolidation
treatment duration.
Keywords: chronic hepatitis B; treatment cessation; HBsAg seroclearance; ethnicity
1. Introduction
With approximately 3% of the worldwide population infected, chronic hepatitis B (CHB) represents
a serious global health problem. Chronic infections are associated with an up to 100-fold increased risk
for liver-related complications, including cirrhosis, decompensation, and hepatocellular carcinoma
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(HCC), ultimately resulting in liver-related death [1]. As such, the hepatitis B virus (HBV) continues to
kill over 700,000 people annually [2].
Curing CHB is challenging. HBV integrates into the host genome and forms covalently closed
circular DNA (cccDNA), a minichromosome in the nucleus of infected hepatocytes, which cannot be
eradicated with the current therapeutic armamentarium [3]. However, seroclearance of the virus from
blood, marked by hepatitis B surface antigen (HBsAg) loss, confers excellent clinical outcomes and is
therefore regarded as the optimal endpoint in CHB treatment [4–7].
Nucleos(t)ide analogues (NA), the first line HBV antivirals, efficiently suppress viral replication,
but HBsAg loss is rarely observed and is estimated to require an average of 36 to 52 years of continuous
treatment [8,9]. Over the last years, withdrawal of NA treatment in long-term virally suppressed
patients that were Hepatitis B e Antigen (HBeAg) negative at the start of treatment has been put
forward as a strategy to increase HBsAg loss rates [3]. Several independent, observational cohort
studies demonstrated high HBsAg loss rates after treatment cessation in these patients, reaching
up to 39% at six years after treatment cessation in Caucasian patients versus a mere 16% in Asian
patients [10–14]. These studies mainly focused on the outcome after treatment cessation in one country,
including either predominantly Caucasian or predominantly Asian patients and were thus not powered
to study the influence of ethnicity on HBsAg seroclearance [10–14]. Nevertheless, it is well appreciated
that ethnicity influences immune responses during a chronic hepatitis B infection [15,16].
In a multi-ethnic cohort of start-of-treatment HBeAg-positive patients who discontinued treatment
following NA-induced HBeAg seroconversion, we recently observed six-fold higher HBsAg loss rates in
Caucasian compared to non-Caucasian patients [17]. However, little is known on the impact of treatment
cessation on HBsAg seroclearance in these patients. Therefore, in the current study, we expanded
our cohort with consecutive patients who continued treatment following HBeAg seroconversion
and explored the relative impact of ethnicity and NA withdrawal on HBsAg seroclearance. We
observed that Caucasian ethnicity is the most important determinant for HBsAg loss after NA-induced
HBeAg-seroconversion, with up to six-fold higher HBsAg loss rates in Caucasians compared to Asians,
irrespective of treatment cessation and consolidation treatment duration.
2. Patients and Methods
2.1. Study Design
We previously established a retrospective, observational cohort of CHB patients (n = 98) who
discontinued treatment following NA-induced HBeAg seroconversion at 20 hospitals in Belgium
(n = 18), the Netherlands (n= 1), and Canada (n= 1) between 1998 and 2016 [17]. We now expanded this
cohort with consecutive patients recruited from all participating centers which continued NA treatment
following treatment-induced HBeAg seroconversion until (1) the end of study inclusion (December
2016), (2) lost to follow-up or (3) HBsAg seroclearance using the same exclusion criteria, definitions
and data collection strategy as described before [17]. Following HBeAg seroconversion, treatment
was continued or interrupted at the discretion of the treating physician, according to the prevailing
guidelines or reimbursement criteria in the different countries. Canadian treatment guidelines state
that treatment cessation may be considered following HBeAg seroconversion with a minimum of
12 months consolidation treatment [18]. Dutch guidelines recommend continuation of antiviral therapy
until HBsAg loss [19]. Belgian reimbursement guidelines impose the discontinuation of treatment
following HBeAg seroconversion [20]. Ethical approval was obtained with the committee for medical
ethics of the Antwerp University Hospital as central medical ethical committee (reference number:
15/44/464). Written informed consent was not deemed necessary by the medical ethical committee
given the retrospective character of the study with inclusion of patients over a long period of time
(1998–2016) and a substantial proportion of the patients that were loss to follow-up or dead by the time
of inclusion.
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2.2. Statistical Analysis
Continuous variables are shown as mean ± standard deviation (SD) or median (interquartile range
(IQR)). Variables were compared between groups using a chi-square test for categorical variables and a
Mann–Whitney U-test or Student t-test for continuous variables. Consolidation treatment duration
was calculated as the time from HBeAg seroconversion until treatment cessation.
A Cox regression model was used to investigate factors associated with HBsAg loss following
HBeAg seroconversion. This approach allows for correction of (1) the time it takes for HBsAg loss
to occur after HBeAg seroconversion, and (2) inter-patient differences in follow-up time. Follow-up
time was calculated as the time from HBeAg seroconversion until HBsAg loss, retreatment initiation
or loss to follow-up. Treatment cessation was included as a time-dependent covariate since patients
in the treatment cessation group discontinued treatment at a variable point in time after HBeAg
seroconversion [21]. Variables with p < 0.100 in univariate analysis were further investigated in
multivariate analyses. To account for possible heterogeneity between Belgian and non-Belgian centers,
Cox regression analyses were stratified by treatment country. A clock-reset approach was applied
to plot Kaplan–Meier curves to illustrate the differences in HBsAg loss rates between patients under
continuous treatment and patients who discontinued treatment [22–24]. Patients who discontinued
treatment were censored in the continuous treatment group at the time of treatment interruption.
The “clock” of these patients was then reset to zero at the time of treatment interruption and further
follow-up of these patients was plotted in the treatment cessation group. Data were analyzed in SPPS
version 24.0 (IBM, Armonk, NY, USA). All statistical tests were two-sided and p-values < 0.05 were
considered statistically significant.
3. Results
3.1. Cohort Characteristics
After expansion of the NA stop cohort with patients who continued treatment, the final cohort
consisted of 178 predominantly male (75.3%) patients of well-balanced, mixed ethnicity (44.4% Asians,
48.9% Caucasians) with NA-induced HBeAg seroconversion after a median treatment duration of
15.5 (8.2–29.3) months [17]. Following HBeAg seroconversion, 105 patients continued treatment for a
median of 11.4 (6.1–18.0) months before withdrawal, whereas 73 patients continued treatment until
the end of study inclusion, loss to follow-up or HBsAg loss. Seven patients were lost to follow-up
immediately after treatment withdrawal (Figure 1). Patient characteristics per treatment status after
HBeAg seroconversion are depicted in Table 1. Overall, characteristics were similar between both
groups. However, the group continuing treatment consisted of significantly more start-of-treatment
cirrhotic patients (41.1% vs. 22.8%, p= 0.012), was treated more frequently with a second-generation NA
(83.5% vs. 41.0%, p < 0.001) and had a significantly shorter follow-up time after HBeAg seroconversion
(median 22.2 vs. 64.2 months, p < 0.001) compared to the treatment stop group.
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Previous interferon treatment (n) 24 (22.6%) 19 (26.4%) 0.722 
HBV genotype * 7A, 1B, 7C, 3D 
10A, 4B, 10C, 5D, 
1G 
0.836 
Treatment start 
HBV DNA (10log) ° 6.86 ± 1.62 7.13 ± 1.85 0.296 
ALT (ULN) °° 2.9 (2.0–5.4) 3.7 (1.7–7.0) 0.728 
Year of treatment start °° 
2006 (2003–
2010) 
2010 (2007–2012) <0.001 
HBeAg 
seroconversion 
HBV DNA (10log) ° 1.75 ± 0.73 1.85 ± 1.08 0.588 
ALT (ULN) °° 0.8 (0.5–1.0) 0.8 (0.6-1.2) 0.230 
Type NA   <0.001 
First generation (Lamivudine-Adefovir- 
Telbivudine) 
62 12  
Second generation (Entecavir- 
Tenofovir) 
43 61  
Time to HBeAg seroconversion (months) °° 17.8 (8.4–31.9) 14.2 (6.0–26.4) 0.611 
FU-time after HBeAg seroconversion 
(months) °° 
64.9 (34.0–97.2) 22.2 (12.0–42.1) <0.001 
Consolidation treatment (months) °° 11.4 (6.1–18.0) NA NA 
FU-time after treatment stop (months) °° 39.8 (13.7–81.4) NA NA 
 
Figure 1. Flowchart of the study cohort according to treatment modality and virologic outcome. NA: 
Nucleos(t)ide Analogues, HBsAg: Hepatitis B surface antigen, HBeAg: Hepatitis B e antigen, CHB: 
chronic hepatitis B. Relapse was defined as a single HBV DNA elevation >2000 IU/mL after treatment 
cessation. 
3.2. HBsAg Loss Following HBeAg Seroconversion 
Thirty patients presented with HBsAg loss at a median of 15.2 (5.2–23.8) months after HBeAg 
seroconversion: 16 on-treatment after a median consolidation therapy of 5.8 (3.3–16.5) months and 14 
Figure 1. Flowchart of the study cohort according to treatment modality and virologic outcome.
NA: Nucleos(t)ide Analogues, HBsAg: Hepatitis B surface antigen, HBeAg: Hepatitis B e antigen,
CHB: chronic hepatitis B. Relapse was defined as a single HBV DNA elevation >2000 IU/mL after
treatment cessation.
Table 1. Patient characteristics according to treatment status after HBeAg seroconversion. *: HBV
Genotyping was available in 48 patients, NA: Nucleos(t)ide analog, ULN: Upper limit of normal, ALT:
Alan ne amino transf rase, ◦: Mean ± SD, ◦◦: Median (IQR), FU: Follow-up. Significa t p-v lues (<0.05)
are marked in bold.
NA Stop Continuing NA p-Value
n = 105 n = 73
Baseline
characteristics
Male gender 78 (74%) 56 (77%) 0.713
Age at treatment start ◦ 40.2 ± 15.2 41.4 ± 15.0 0.484
Ethnicity 0.874
Asian (n) 46 33
Black (n) 7 5
Caucasian (n) 52 34
Other (n) 1
Cirrhosis (n) 24 (22.8%) 30 (41.1%) 0.012
Previous interferon treatment (n) 24 (22.6%) 19 (26.4%) 0.722
HBV genotype * 7A, 1B, 7C, 3D 10A, 4B, 10C, 5D, 1G 0.836
Treatment start
HBV DNA (10log) ◦ 6.86 ± 1.62 7.13 ± 1.85 0.296
ALT (ULN) ◦◦ 2.9 (2.0–5.4) 3.7 (1.7–7.0) 0.728
Year of treatment start ◦◦ 2006 (2003–2010) 2010 (2007–2012) <0.001
HBeAg
seroconversion
HBV DNA (10log) ◦ 1.75 ± 0.73 1.85 ± 1.08 0.588
ALT (ULN) ◦◦ 0.8 (0.5–1.0) 0.8 (0.6–1.2) 0.230
Type NA <0.001
First generation
(Lamivudine-Adefovir-Telbivudine) 62 12
Second generation (Entecavir-Tenofovir) 43 61
Time to HBeAg seroconversion (months) ◦◦ 17.8 (8.4–31.9) 14.2 (6.0–26.4) 0.611
FU-time after HBeAg seroconversion (months) ◦◦ 64.9 (34.0–97.2) 22.2 (12.0–42.1) <0.001
Consolidation treatment (months) ◦◦ 11.4 (6.1–18.0) NA NA
FU-time after treatment stop (months) ◦◦ 39.8 (13.7–81.4) NA NA
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3.2. HBsAg Loss Following HBeAg Seroconversion
Thirty patients presented with HBsAg loss at a median of 15.2 (5.2–23.8) months after HBeAg
seroconversion: 16 on-treatment after a median consolidation therapy of 5.8 (3.3–16.5) months and
14 off-treatment at a median of 9.7 (5.3–20.7) months after treatment cessation. Virologic outcomes
after treatment cessation have been described elsewhere [17]. A summary is depicted in Figure 1.
3.3. Caucasian Ethnicity, but not Treatment Cessation Is Associated with HBsAg Loss
Factors assessed to predict HBsAg loss after HBeAg seroconversion in the entire cohort are
displayed in Table 2. Caucasian ethnicity (Hazard Ratio (HR) 6.70, p = 0.001), higher HBV DNA
(HR 2.29 per log increment, p < 0.001), higher gamma-GT (HR 1.02 per 10 units increment, p = 0.006)
and older age at start of treatment (HR 1.03 per year increment, p = 0.006) were associated with HBsAg
loss in a univariate cox regression model. In multivariate analyses, Caucasian ethnicity (Figure 2 and
Table 2) and higher HBV DNA levels at the start of treatment continued to be significantly associated
(Table 2). The HBV genotype was not associated with HBsAg loss (p = 0.812) in a subpopulation of
48 patients in which HBV genotyping was available.
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Figure 2. Kaplan–Meier curve showing the difference in HBsAg loss rates between patients of
Caucasian and non-Caucasian ethnicity irrespective of treatment status after HBeAg seroconversion.
* p-value = log-rank. HBsAg: Hepatitis B surface Antigen, HBeAg: Hepatitis B e Antigen.
Overall, mean annual HBsAg loss rates were 5.4% and 5.1% on- and off-treatment respectively
(p = 0.561). In Cox regression analyses, treatment cessation was not associated with HBsAg loss (HR 1.45,
p = 0.372, Table 2, Figure 3A). Prolonging treatment duration following HBeAg seroconversion to at
least 6 (HR 1.73, p = 0.289, Figure 3B) or 12 months (HR 1.52, p = 0.525 Figure 3C) before cessation, did
not result in higher HBsAg loss rates compared to patients that continued antiviral treatment. Anti-HBs
antibody (Anti-HBs) development was observed in 12 patients on- and seven patients off-treatment.
Patients with on-treatment HBsAg loss tended to develop anti-HBs more rapidly, but there was no
difference in the cumulative rate of anti-HBs development two years after HBsAg loss (68.9% vs. 66.6%,
p = 0.754) (Figure 3D .
To control f r a possible imbalance in our cohort egarding cirrhosi tatus and type of NA use, we
perform d a propensity score-adjuste Cox regression analysis. Propensity scores w re derived from a
logistic regression model assessing the correlation betwee cirrhosis status, NA type, and (1) Caucasian
ethnicity or (2) treatment cessation. Results showed that propensity score adjustment did not change
our observations (Table S1), indicating that the imbalance in cirrhosis status and type of NA did not
impact our results.
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Table 2. Univariate and multivariate Cox regression model to predict HBsAg loss following treatment-induced HBeAg seroconversion in the entire patient cohort.
HR: Hazard ratio, C.I.: Confidence interval, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, Gamma-GT: Gamma-glutamyl transferase. HBsAg:
Hepatitis B surface Antigen, HBeAg: Hepatitis B e Antigen. Factors with p < 0.100 in univariate analysis were further investigated in multivariate models. Treatment
cessation was investigated as a time-dependent covariate.
Univariate Multivariate Model 1 Multivariate Model 2 Multivariate Model 3 Multivariate Model 4
p HR (95% C.I.) p HR (95% C.I.) p HR (95% C.I.) p HR (95% C.I.) p HR (95% C.I.)
Baseline
characteristics
Caucasian ethnicity 0.001 6.70 (2.26–21.40) 0.032 3.79 (1.12–12.77) 0.047 8.09 (1.03–63.81) 0.008 6.03 (1.59–22.84) 0.006 5.25 (1.62–17.03)
Male gender 0.198 2.01 (0.70–5.87)
Prior interferon treatment 0.724 1.16 (0.51–2.62)
Cirrhosis 0.192 0.61 (0.28–1.29)
Treatment start
Age at start of treatment (years) 0.006 1.03 (1.01–1.05) 0.095 1.02 (1.00–1.05) 0.169 1.02 (0.99–1.05) 0.129 1.02 (1.00–1.04)
ALT (per 10 units increment) 0.724 1.00 (0.99–1.01)
AST (per 10 units increment) 0.475 1.00 (0.99–1.02)
Gamma-GT (per 10 units increment) 0.006 1.02 (1.01–1.04) 0.091 1.02 (1.00–1.03)
HBV DNA (10log) <0.001 2.29 (1.60–3.27) <0.001 1.90 (1.36–2.66)
Platelets (per 104 units increment) 0.989 1.00 (0.94–1.06)
HBeAg
seroconversion
ALT (per 10 units increment) 0.005 1.07 (1.02–1.13) 0.141 1.06 (0.98–1.13) 0.028 1.06 (1.01–1.11)
AST (per 10 units increment) 0.432 1.07 (0.91–1.26)
Gamma-GT (per 10 units increment) 0.106 1.04 (0.99–1.09)
HBV DNA (10log) 0.059 1.63 (0.98–2.70) 0.751 1.11 (0.59–2.07)
Platelets (per 104 units increment) 0.273 1.03 (0.98–1.09)
Time to HBV DNA <2000 IU/mL (years) 0.998 1.00 (0.74–1.35)
Time to HBeAg seroconversion (years) 0.381 0.91 (0.73–1.13)
First/second generation NA 0.823 1.09 (0.51–2.33)
Treatment
cessation
Overall (Yes/No) 0.372 1.45 (0.64–3.29)
At least 6 months consolidation 0.289 1.73 (0.63–4.79)
At least 12 months consolidation 0.525 1.52 (0.42–5.47)
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Figure 3. Kaplan–Meier curves showing (1) the cumulative probability of HBsAg loss after HBeAg
seroconversion using a clock-reset approach (A–C) and (2) the cumulative probability of anti-HBs
development after HBsAg loss (D). Analysis of (A) the entire cohort. Origin of X-axis is set at HBeAg
seroconversion. (B) Patients with at least six months consolidation treatment. Origin of X-axis is set at
six months after HBeAg seroconversion. (C) Patients with at least 12 months consolidation treatment.
Origin of X-axis is set at 12 months after HBeAg seroconversion and (D) all patients with HBsAg loss. As
described in the Methods section, patients in the continuous treatment group were censored at the time
of HBsAg loss, loss to follow-up or treatment cessation. Patients in the treatment cessation group were
censored at the time of HBsAg loss, loss to follow-up or retreatment initiation. Patients were considered
continuing treatment until treatment was discontinued and were censored in the group continuing
treatment at the time of treatment cessation. The moment of treatment cessation was subsequently
considered as time zero for further follow-up in the treatment stop group. * p-value = log-rank, HBeAg:
Hepatitis B e antigen, HBsAg: Hepatitis B surface antigen, N : Nucleos(t)ide An logues, Anti-HBs:
Anti hepatitis B surf ce antige antibody. FU: Follow-Up.
4. Discussion
In the present study, we investigated HBsAg loss following NA-induced HBeAg seroconversion
in a multicentric, international CHB cohort that was well-balanced for ethnicity. We demonstrate that
Caucasian ethnicity, but not treatment cessation is associated with HBsAg loss.
In contrast to previous reports in start-of-treatment HBeAg-negative patients, treatment cessation
did not increase the chance of subsequent HBsAg loss in our cohort. In long-term virally suppressed,
start-of-treatment HBeAg-negative patients, treatment cessation has been suggested to reinvigorate
immune responses leading to subsequent HBsAg loss [13]. HBeAg seroconversion marks improved
immune control [3]. As such, patients with a recent NA-induced HBeAg seroconversion may be prone
to clear HBsAg through this improved immune control, regardless of treatment cessation.
Interestingly, irrespective of treatment cessation, Caucasian patients had a >6-fold increased
chance of HBsAg loss compared to other ethnicities, which comprised almost half of the entire cohort.
Previous studies corroborate an up to 2.8-fold lower chance of HBsAg loss in Asian patients during the
natural history of a CHB infection [25,26]. In a subgroup (n = 48) of our cohort with an available HBV
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genotype, this ethnic difference in HBsAg loss rates was not related to the HBV genotype. Host factors
such as Human Leukocyte Antigen (HLA) polymorphisms may evidently contribute to the observed
differences in HBsAg loss rates [27]. Polymorphisms of Major Histocompatibility Complex class II
proteins, have been shown to be associated with HBV persistence, seroconversion, seroclearance, and
disease progression, but only in patients with a certain ethnic background. For example, the HLA-DR
polymorphism rs 9277535 (550 A/G) is strongly associated with chronic hepatitis B and its outcomes in
Asian, but not in African-American or Caucasian patients [15,16].
Although this is, to our knowledge, the largest real-life, multi-ethnic cohort study as of today
assessing HBsAg loss in patients with NA treatment-induced HBeAg seroconversion, still there are
some limitations. First, the study design was intrinsically retrospective. As such, a variation in the
number of lab values available per patient cannot be overcome and the duration of infection was mostly
unknown. In addition, HBV genotypes were available in only 48 patients as HBV genotyping was
mostly not performed during routine clinical practice. Nonetheless, most patients were followed-up
every three to six months according to international guidelines and the age at the start of treatment was
not associated with HBsAg loss in multivariate modelling. Second, we pooled patients from 20 centres
in Belgium, the Netherlands, and Canada over a long period of time (1998–2016), possibly resulting
in a heterogeneous study population. Nevertheless, data were collected in a systematic manner in
all centres and correction of the statistical analyses for possible heterogeneity did not influence the
results. Third, the group continuing treatment contained significantly more cirrhotic patients, was
more frequently treated with second-generation NA and had a shorter follow-up time. However,
because (1) cirrhosis and the type of NA were not associated with HBsAg loss in our Cox regression
model, (2) propensity score-adjusted Cox regression analysis to correct for differences in NA type and
cirrhosis status yielded similar results (Table S1), and (3) Cox regression analyses and Kaplan–Meier
curves inherently correct for a difference in follow-up time, we are convinced that this unbalance did
not impact our results.
In conclusion, ethnicity is the most important determinant for HBsAg loss after NA-induced
HBeAg seroconversion, with an up to six-fold increased chance of HBsAg loss in Caucasian compared
to non-Caucasian patients, irrespective of treatment cessation and consolidation treatment duration.
Further prospective studies should unravel the immunological events in order to improve functional
cure rates of future HBV antivirals.
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